Lenalidomide for mantle cell lymphoma. Issue 3 (June 2015)

• Record Type: Journal Article
• Authors: Skarbnik, Alan P; Goy, Andre H
• Is Part Of: Expert review of hematology. Volume 8:Issue 3(2015)
• Page Start: 257
• Page End: 264
• Publication Date: 2015-06
• Subjects: IMiD -- immunomodulatory -- lenalidomide -- mantle cell lymphoma -- revlimid; Hematology -- Periodicals; 616.15005
• DOI: 10.1586/17474086.2015.1035706
• Languages: English
• ISSNs: 1747-4086

Abstract

Abstract : Mantle cell lymphoma accounts for 6% of all non-Hodgkin lymphomas. It is a biologically and clinically heterogeneous disease and treatment may be difficult, since most patients present at an older age, being unable to undergo intensive chemotherapy. Lenalidomide is an approved medication for relapsed mantle cell lymphoma in patients who received at least two lines of therapy, including bortezomib. New insights into the mechanisms of action of lenalidomide provided ground for novel combinations that may be more tolerable, while still efficient, for this patient population. In this review, we evaluate the current paradigm for lenalidomide in mantle cell lymphoma.